SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2627Incyte Has Plenty of Upside this year Case outlined here... earningsview.blogsDoctor Zeus-1/13/2011
2626finance.yahoo.com FDA Grants Supplemental Approval for ACTEMRA® (tocilizumscaram(o)uche-1/5/2011
2625Thanks for posting that. My impression was that this P3 was very low risk based fred hayes-12/21/2010
2624Incyte Announces Positive Top-Line Results from COMFORT-I Pivotal Phase III TriaLJM-12/20/2010
2623From drbio45 on IHub, Aschoff addresses the the transfusion/anemia isssue (no lotuck-12/7/2010
2622Shareholders would have been better served if the entire piper jaffray conferencsoftware salesperson-11/30/2010
2621new trial, phase I in "up to third generation Japanese, that is defined as scaram(o)uche-11/28/2010
2620Maybe they’ll be able to take INHX’s FV-100.DewDiligence_on_SI-11/15/2010
2619>>The age limit for shingles vaccination should soon drop to 50 But one iBiomaven-11/15/2010
2618First blush, Pfizer is wishing that it was first mover, but with 050. :-) Thisscaram(o)uche-11/11/2010
261711/10/10 ACR 050 cc 1) No neutrophil issues; no kidney effects 2) Conclusions:software salesperson-11/10/2010
2616Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase tnsaf-11/10/2010
2615Agreed - plus he's into crossword puzzles!tom pope-11/9/2010
2614Where would we be without Sales? Thanks...fred hayes-11/9/2010
261311/9/10 cc notes 1. Opening remarks 24 week P2a 050 data and webcast tomorrow software salesperson211/9/2010
2612some potentially good news from the Pfizer release.... <i>The increases sscaram(o)uche-11/8/2010
2611Looks like Pfizer's drug had results in the same general ballpark, although Biomaven-11/7/2010
2610More News related to INCY * Incyte Corp (INCY) Achieves $50M in Milestones ewolf-11/2/2010
2609WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (NASDAQ:INCY - News) annonigel bates-11/2/2010
2608quantman, in May, he said: (i) 050 - - positive topline 12 week P2 results thasoftware salesperson-10/27/2010
2607Hi there SS Correct me if I'm wrong please.........but the abstract is justquantman-10/27/2010
2606ACR 11/10 2172 A Randomized Dose-Ranging, Placebo-Controlled Study of INCB0280software salesperson-10/26/2010
260528050 moves to Ph2b in RA along with a milestone payment. Name of the compound Biotech Jim-10/20/2010
2604Stock has been a non-stop monster since one contributor went all Pavlovian over scaram(o)uche-10/12/2010
2603Things may not be as they seem at first glance. It's always good to read allquantman19/25/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News